Matinas BioPharma Holdings (MTNB) Operating Expenses (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Operating Expenses data on file, last reported at $1.9 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $1.9 million, down 0.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (down 66.32% YoY), and the FY2025 annual result was $7.0 million, down 71.7% from the prior year.
• Operating Expenses improved to $1.9 million in Q1 2026 per MTNB's latest filing, from $1.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $8.5 million in Q4 2024 and troughed at $1.6 million in Q3 2025.
• A 5-year average of $5.1 million and a median of $5.9 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 45.9% in 2022, then plunged 81.11% in 2025.
• A 5-year view of Operating Expenses shows it stood at $6.5 million in 2022, then retreated by 10.03% to $5.9 million in 2023, then surged by 43.86% to $8.5 million in 2024, then sank by 81.11% to $1.6 million in 2025, then climbed by 21.0% to $1.9 million in 2026.
• Business Quant data shows MTNB's Operating Expenses at $1.9 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.